Recruiting
Breast cancer+1
RecruitingStudy on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy
Investigational
Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy
Investigational
- Disease:Breast cancerHER2 positive breast cancer
- Substances:SargramostimL-Isoleucyl-L-Isoleucyl-L-Seryl-L-Alanyl-L-Valyl-L-Valyl-Glycyl-L-Isoleucyl-L-Leucine
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Sargramostim
